Overview

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

Status:
Completed
Trial end date:
2020-02-29
Target enrollment:
Participant gender:
Summary
Multicenter, open-label dose-escalation study
Phase:
Phase 1
Details
Lead Sponsor:
Collaborative Medicinal Development Pty Limited
Treatments:
Copper